The FAST-CTO trial demonstrated the safety and efficacy of the CrossBoss and Stingray Coronary CTO Crossing and Re-Entry devices to recanalize coronary CTOs in comparison to historical controls.
Use of the CrossBoss and Stingray Crossing and Re-Entry devices result in a high technical success, 77%, without increasing complications.1
Procedural success was improved with a 28.1% reduction in mean procedure time (minutes) as well as a reduction in fluoroscopy time.1
Patrick Whitlow MD, William Lombardi MD, Michael Wyman MD, Craig Thompson MD
Cleveland Clinic, PeaceHealth Medical Center/St Joseph Hospital, Torrance Memorial Medical Center, Yale University School of Medicine